Zacks Research Brokers Decrease Earnings Estimates for CPRX

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Equities research analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $2.02 per share for the year, down from their previous forecast of $2.07. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ FY2026 earnings at $2.25 EPS and FY2027 earnings at $2.37 EPS.

Several other equities analysts also recently issued reports on CPRX. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Bank of America restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $25.74 on Monday. Catalyst Pharmaceuticals has a one year low of $14.47 and a one year high of $26.16. The company has a market cap of $3.13 billion, a PE ratio of 21.81, a P/E/G ratio of 3.31 and a beta of 0.84. The firm’s 50 day simple moving average is $22.46 and its 200 day simple moving average is $21.67.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Summit Investment Advisors Inc. boosted its holdings in Catalyst Pharmaceuticals by 5.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 580 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Catalyst Pharmaceuticals by 6.2% in the fourth quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 875 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Catalyst Pharmaceuticals by 0.3% in the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock valued at $6,518,000 after purchasing an additional 952 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 1,000 shares in the last quarter. Finally, PDT Partners LLC boosted its holdings in Catalyst Pharmaceuticals by 5.2% during the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 1,030 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.